- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03065478
Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy (STEFANO)
An Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving Chemotherapy-induced peripherAl NeurOpathy in Patients With Colon or Breast Cancer After End of Adjuvant Therapy
Study Overview
Status
Intervention / Treatment
Detailed Description
CIPN is a common side effect of many chemotherapeutic agents and often results in dose limitation, switch to less efficacious agents or even therapy discontinuation. CIPN mainly affects sensory nerves, while motor or autonomic nerve injury is rare. Therefore, most patients with CIPN experience numbness, tingling, hyperesthesia, loss of vibratory perception, and burning pain. Due to the vulnerability of the long nerves, CIPN typically appears in a 'stocking and glove' distribution.
Chemotherapeutic agents that cause CIPN include platinum compounds (e.g., cisplatin, oxaliplatin), antitubulins (vinca alkaloids (e.g., vincristine) and taxanes (e.g., docetaxel, paclitaxel)), proteasome inhibitors (e.g., bortezomib) and immunomodulatory drugs (e.g., lenalidomide).
Platinum compounds are known to accumulate in the dorsal root ganglion (DRG) leading to cell death in sensory neurons. DRG death may account for chronic sensory neuropathy, which manifests primarily as sensory paresthesias, dysesthesias and sensory ataxia most often located in the extremities and persists between cycles. In addition, Oxaliplatin directly regulates the gating of axonal voltage-gated sodium channels, inducing an acute neurotoxicity which is characterized by peripheral nerve hyperexcitability. Symptoms, like sensitivities to touching cold items, discomfort swallowing cold liquids, throat discomfort, and muscle cramps, occur during or shortly after the infusion.
Taxanes are known to cause disruption of microtubule function and therefore microtubule-based axonal transport. In addition, they interfere with macrophage activation in both the DRG and peripheral nerve, as well as microglial activation within the spinal cord. These effects result in a distal axonopathy also referred to as the dying-back phenomenon.
The effectiveness of OnLife® in improving CIPN is based on a patented fatty acid group (FAG) that comprises palmitoylethanolamide (PEA), alpha-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), linoleic acid, oleic acid, palmitic acid, stearic acid, arachidic acid and myristic acid.
PEA, one main component of OnLife®, is an endogenous fatty acid amide belonging to the class of endocannabinoids and has been shown to have anti-inflammatory, antinociceptive, neuroprotective and anticonvulsant properties. It is synthesized in response to several inflammatory and painful disorders (e.g., intestinal inflammation and neuropathic pain) in order to counteract these pathological states. Clinical research revealed that treatment with exogenous PEA is effective and safe in various neuropathological conditions, including chronic idiopathic axonal neuropathy, diabetic neuropathy, nerve compression syndromes, as well as chemotherapy-induced neuropathic pain.
PEA exerts its analgesic and anti-inflammatory functions in the peripheral nervous system through its action on sensory neurons and on non-neuronal cells involved in inflammation, such as mast cells and macrophages. It indirectly activates cannabinoid receptor signaling by inhibiting the hydrolysis of endocannabinoids. This suppresses nociceptive behaviors and counteracts macrophage and mast cell activation, thereby reducing pain and other inflammatory symptoms. Another biological target of PEA is the nuclear peroxisome proliferator-activated receptor (PPAR)-alpha, expressed in various cells implicated in peripheral nociception, including dorsal DRG neurons and macrophages. Binding of PEA to PPAR-alpha ultimately results in reduced transcription of pro-inflammatory genes (e.g., TNF-alpha, IL-6, COX-2, iNOS) as well as repressed activity of pro-inflammatory transcription factors. In addition, there is some evidence that binding of PEA to PPAR-alpha may modulate excitability of primary sensory neurons by direct and indirect mechanisms.
The other fatty acids included in OnLife® have also been shown to have anti-inflammatory properties.
Currently, a study evaluating the efficacy and safety of OnLife® in patients with CIPN is carried out at the St. Savvas Anticancer Hospital, Athens by Dr. J. Skarlatos. First results suggest that OnLife® is reducing pain, numbness and tingle and improving heat/cold sensitivity as assessed by the physician. PRO, using the DN4 (Douleur Neuropathique 4) questionnaire, revealed a reduction of the score for diagnosing neuropathic pain during OnLife® application. Moreover, no patient showed a product-related side effect (date on file, unpublished).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Freiburg im Breisgau, Baden-Württemberg, Germany, 79110
- Praxis für interdisziplinäre Onkologie & Hämatologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients with colon or breast cancer that have finished adjuvant oxaliplatin-containing or paclitaxel chemotherapy, respectively
- End of adjuvant chemotherapy does not date back more than 4 months
- Presence of CIPN grade 1-3 (according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03)
- Decision for treatment with OnLife® (Baseline assessment has to be done before first intake of OnLife®)
- Written informed consent
- Able to understand and willing to complete study and patient-reported assessment instruments
Exclusion Criteria:
- Presence of sensory and/or motor disturbances due to other neurological diseases
- Alcohol abuse
- Pregnancy or breast-feeding
- Severe difficulty swallowing
- Intolerance to one of the ingredients of OnLife®
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Colon carcinoma
Dietary supplementation with "OnLife" to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy.
|
Daily dosing of dietary supplement OnLife
|
Mamma carcinoma
Dietary supplementation with "OnLife" to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen.
|
Daily dosing of dietary supplement OnLife
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the CIPN
Time Frame: 16 month
|
Incidence of grade 0/1/2/3/4 peripheral sensory and/ or motor neuropathy according to CTCAE v4.03 after end of adjuvant oxaliplatin-containing regimen (colon cancer) or adjuvant paclitaxel regimen (breast cancer)
|
16 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported outcome: EORTC QLQ-C30
Time Frame: 16 month
|
Questionnaire EORTC QLQ-C30 is used to determine patients' health-related quality of life.
|
16 month
|
Patient reported outcome: EORTC QLQ-CIPN20
Time Frame: 16 month
|
Questionnaire EORTC QLQ-CIPN20 is used to elicit patients' experience of symptoms and functional limitations related to CIPN.
|
16 month
|
Concomitant medication used for the treatment of neuropathic pain
Time Frame: 16 month
|
Drug treatment of neuropathic pain is observed over the time of the OnLife® application and the month after the end of OnLife® application
|
16 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthias Zaiss, Dr., Praxis für interdisziplinäre Onkologie & Hämatologie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IOM-080353
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CIPN in Adjuvant Colon Cancer Patients
-
Association Sud pour la Recherche en OncogériatrieCompletedColon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting | Aged 70 or OlderFrance
-
Centre Antoine LacassagneCompletedNon-metastatic Patients With Breast Cancer | Non-metastatic Patients With Colon Cancer | Non-metastatic Patients With Rectal Cancer | Patients Undergoing Adjuvant ChemotherapyFrance
-
South Egypt Cancer InstituteCompletedImmunity Factors in Cancer Colon PatientsEgypt
-
Second Affiliated Hospital, School of Medicine,...RecruitingStage II Colon Cancer | Stage III Colon Cancer | Adjuvant TherapyChina
-
Institut fuer FrauengesundheitNovartis; ClinSolUnknownis to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.Germany
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingAdjuvant Chemotherapy | Stage II Colon Cancer
-
Rambam Health Care CampusUnknownNeeds and Demands of Oncology Patients | Breast Cancer Patients. | Colon Cancer Patients.Israel
-
Heidelberg UniversityWithdrawnDistress in Caregivers of Cancer Patients
-
AstraZenecaCompletedPostoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) PatientsRussian Federation
-
China Medical University HospitalCompletedIL-17+ CD8 T Cells in Cancer PatientsTaiwan
Clinical Trials on OnLife
-
Centre Georges Francois LeclercRecruiting